Intranasal interferon as protection against experimental respiratory coronavirus infection in volunteers
Open Access
- 1 November 1983
- journal article
- research article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 24 (5), 713-715
- https://doi.org/10.1128/aac.24.5.713
Abstract
In a double-blind, placebo-controlled study, self-administered intranasal human interferon alpha A produced by recombinant DNA technology was given both before and after virus challenge with a respiratory coronavirus. The incidence of colds, the severity of symptoms and signs, and virus replication were all reduced in subjects receiving interferon as compared with those given placebo.This publication has 6 references indexed in Scilit:
- An effective dosage regimen for prophylaxis against rhinovirus infection by intranasal administration of HuIFN-α2Antiviral Research, 1983
- Clones of MRC-C cells may be superior to the parent line for the culture of 229E-like strains of human respiratory coronavirusJournal of Virological Methods, 1983
- Failure of oral 4′, 6-dichloroflavan to protect against rhinovirus infection in manArchiv für die gesamte Virusforschung, 1983
- PREVENTION OF RHINOVIRUS COLDS BY HUMAN INTERFERON ALPHA-2 FROM ESCHERICHIA COLIThe Lancet, 1982
- Purified interferon as protection against rhinovirus infection.BMJ, 1982
- INHIBITION OF RESPIRATORY VIRUS INFECTION BY LOCALLY APPLIED INTERFERONThe Lancet, 1973